Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Marker Therapeutics Inc (MRKR)
NASDAQ:MRKR
Holding MRKR?
Track your performance easily
MRKR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.83 - $5.99
Previous CloseN/A
Volume39.59K
Average Volume (3M)92.61K
Market Cap
$22.91M
Enterprise Value$16.16M
Total Cash (Recent Filing)$7.85M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.18
Next Earnings
Mar 13, 2025EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.08
Shares Outstanding10,707,295
10 Day Avg. Volume72,418
30 Day Avg. Volume92,611
Standard Deviation0.32
R-Squared0.06
Alpha-0.00848
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)3.54
Price to Cash Flow (P/CF)4.00
P/FCF Ratio4.00
Enterprise Value/Market Cap0.71
Enterprise Value/Revenue2.19
Enterprise Value/Gross Profit4.88
Enterprise Value/Ebitda-1.64
Forecast
1Y Price Target
$19.00Price Target Upside889.58% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
Marker Therapeutics News
PremiumCompany Announcements
Marker Therapeutics Advances in Clinical Trials and Finances
Ownership Overview
18.25% Insiders
2.97% Mutual Funds
<0.01% Other Institutional Investors
76.40% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
MRKR FAQ
What was Marker Therapeutics Inc’s price range in the past 12 months?
Marker Therapeutics Inc lowest stock price was $1.83 and its highest was $5.99 in the past 12 months.
What is Marker Therapeutics Inc’s market cap?
Marker Therapeutics Inc’s market cap is $22.91M.
When is Marker Therapeutics Inc’s upcoming earnings report date?
Marker Therapeutics Inc’s upcoming earnings report date is Mar 13, 2025 which is in 41 days.
How were Marker Therapeutics Inc’s earnings last quarter?
Marker Therapeutics Inc released its earnings results on Nov 14, 2024. The company reported -$0.26 earnings per share for the quarter, beating the consensus estimate of -$0.39 by $0.13.
Is Marker Therapeutics Inc overvalued?
According to Wall Street analysts Marker Therapeutics Inc’s price is currently Undervalued.
Does Marker Therapeutics Inc pay dividends?
Marker Therapeutics Inc does not currently pay dividends.
What is Marker Therapeutics Inc’s EPS estimate?
Marker Therapeutics Inc’s EPS estimate is -0.28.
How many shares outstanding does Marker Therapeutics Inc have?
Marker Therapeutics Inc has 10,707,295 shares outstanding.
What happened to Marker Therapeutics Inc’s price movement after its last earnings report?
Marker Therapeutics Inc reported an EPS of -$0.26 in its last earnings report, beating expectations of -$0.39. Following the earnings report the stock price went down -12.286%.
Which hedge fund is a major shareholder of Marker Therapeutics Inc?
Currently, no hedge funds are holding shares in MRKR
---
Marker Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$19.00 (889.58% Upside)
$19.00 (889.58% Upside)
Hedge Fund Trend
Decreased
By 294.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.8M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-48.68%
12-Months-Change
Fundamentals
Return on Equity
-79.76%
Trailing 12-Months
Asset Growth
-44.01%
Trailing 12-Months
Company Description
Marker Therapeutics Inc
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which specializes in the development and commercialization of novel cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company was founded on October 22, 1991 and is headquartered in Houston, TX.
---
MRKR Stock 12 Month Forecast
Average Price Target
$19.00
▲(889.58% Upside)
Technical Analysis
Bluebird Bio
―
Karyopharm Therapeutics
―
Iovance Biotherapeutics
―
Adaptimmune Therapeutics
―
Crispr Therapeutics AG
―
Best Analysts Covering MRKR
1 Year
1 Year Success Rate
0/2 ratings generated profit
1 Year Average Return
-50.15%
reiterated a buy rating 3 months ago
Copying Aydin Huseynov's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -50.15% per trade.
---